Immunogenomic Biomarkers and Validation in Lynch Syndrome

Area of Science:

• Genetics and Genomics
• Immunology
• Oncology

Background:

• Lynch syndrome (LS) is an inherited disorder increasing risk for early-onset colorectal and non-colorectal cancers due to DNA repair gene mutations.
• Mutations cause neoantigen formation, triggering immune responses, but current cancer screening adherence in LS variant heterozygotes (LSVH) is low.
• The potential of immunogenomic components as biomarkers in LS remains largely unexplored.

Purpose of the Study:

• To investigate the feasibility of identifying personalized, novel immunogenomic biomarkers in LSVH.
• To explore the potential of these biomarkers in various clinical scenarios within the LSVH population.
• To hypothesize that LSVH produce measurable immunogenomic components in blood that correlate with cancer onset and stage.

Main Methods:

• Discussion of the feasibility of identifying and validating immunogenomic biomarkers.
• Focus on neoantigen formation as a source of potential biomarkers.
• Exploration of blood-based immunogenomic components for clinical application.

Main Results:

• Hypothesizes that LSVH produce measurable and dynamic immunogenomic components in blood.
• Proposes that these quantifiable components correlate with cancer onset and stage.
• Discusses the potential for personalized biomarker identification.

Conclusions:

• LSVH may generate unique immunogenomic signatures linked to cancer development.
• Further research is warranted to validate these potential biomarkers for clinical use.
• Novel blood-based biomarkers could improve cancer screening and management in LSVH.